APLT Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Applied Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.41 |
| 52 Week High | US$10.62 |
| 52 Week Low | US$0.29 |
| Beta | 2.01 |
| 1 Month Change | 18.55% |
| 3 Month Change | -32.85% |
| 1 Year Change | -91.13% |
| 3 Year Change | -76.72% |
| 5 Year Change | -99.05% |
| Change since IPO | -95.64% |
Recent News & Updates
Recent updates
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Nov 15
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
Sep 18Applied Therapeutics: Pushing Towards FDA Approval
Sep 04We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely
Aug 01Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases
May 28Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
Feb 16Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?
Feb 16Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
Nov 13We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
Aug 11We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
May 19Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Jan 19Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?
Nov 11Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Aug 13Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
May 15Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)
Feb 26How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?
Feb 18Shareholder Returns
| APLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.2% | -6.1% | 1.3% |
| 1Y | -91.1% | -13.2% | 8.2% |
Return vs Industry: APLT underperformed the US Biotechs industry which returned -13.5% over the past year.
Return vs Market: APLT underperformed the US Market which returned 7.7% over the past year.
Price Volatility
| APLT volatility | |
|---|---|
| APLT Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: APLT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APLT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 35 | Les Funtleyder | www.appliedtherapeutics.com |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.
Applied Therapeutics, Inc. Fundamentals Summary
| APLT fundamental statistics | |
|---|---|
| Market cap | US$59.46m |
| Earnings (TTM) | -US$105.62m |
| Revenue (TTM) | US$455.00k |
127.5x
P/S Ratio-0.5x
P/E RatioIs APLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLT income statement (TTM) | |
|---|---|
| Revenue | US$455.00k |
| Cost of Revenue | US$48.74m |
| Gross Profit | -US$48.29m |
| Other Expenses | US$57.34m |
| Earnings | -US$105.62m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | -10,612.97% |
| Net Profit Margin | -23,214.07% |
| Debt/Equity Ratio | 0% |
How did APLT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 06:58 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Applied Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Carter Gould | Barclays |
| Paul Choi | Goldman Sachs |